Osteoclast-Derived Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss.
Sacha FlammierOlivier PeyruchaudFanny BourguillaultFrançois DuboeufJean-Luc DavignonDerek D NormanSylvie IsaacHubert MarotteGabor TigyiIrma Machuca-GayetFabienne CouryPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
Our results identify ATX as a novel OC factor that specifically controls inflammation-induced bone erosions and systemic bone loss. Therefore, ATX inhibition offers a novel therapeutic approach for potentially preventing bone erosion in patients with RA.